Cell Cycle/Checkpoint

PROTAC CDK9 degrader-2, potent, selective, IC50 17 μM in MCF-7, wogonin-derived, targets CRBN.

N6-Methyl-2’-O-(2-methoxyethyl) adenosine, a purine nucleoside analog, exhibits broad antitumor activity, particularly against indolent lymphoid malignancies.

CDK2/PIM1-IN-1 is an inhibitor of the kinases CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM). It can induce apoptosis (cell death) and reduce the expression of TNF-α, which promotes tumors. CDK2/PIM1-IN-1 exhibits antitumor activity.

CDK2, a Ser/Thr kinase, is akin to yeast cdc28 and human Cdk1, crucial for cell division.

CD532 hydrochloride, potent Aurora A inhibitor (IC50=45 nM), hampers MYCN protein, changes AURKA's shape, aids cancer research.

KIF2C-IN-1 (Compound 7S9) is a selective and potent small molecule inhibitor of KIF2C. It stabilizes the interaction between KIF2C and microtubule proteins, preventing the depolymerization of polyglutamylated microtubules. KIF2C-IN-1 enhances the cytotoxicity of Paclitaxel in Paclitaxel-resistant triple-negative breast cancer (TNBC) cells and, when combined with Paclitaxel, significantly reduces tumor growth in mouse models.

Chrexanthomycin C, orally active, binds DNA (G4C2)4 G4, Kd 2.8 mM, potential in ALS research.

Fibronectin CS1 peptide inhibits tumor metastasis, lacking RGD domain; may aid cancer therapy.

5'-O-TBDMS-N2-ibu-dG: a nucleoside derivative with strong anti-BVDV activity, useful in lead compound synthesis.

Pyrindamycin A is an antibiotic that inhibits DNA synthesis,and shows antitumor activities against murine leukemia.

Emofolin sodium, a synthetic folate analogue, inhibits DNA/RNA/protein synthesis by blocking dihydrofolate reductase.

PROTAC CDK9 degrader-7 is a proteolysis-targeting chimera (PROTAC) specifically designed to target and mediate the degradation of Cyclin-Dependent Kinase 9 (

Deoxythymidine-5'-triphosphate (dTTP) is a nucleoside triphosphate involved in DNA synthesis.

PAT-LM1 is a human monoclonal antibody that targets NRB54/NONO. It is applicable in the study of hematological malignancies.

LY2812223: selective mGlu2 agonist; binds mGlu2/mGlu3 (Ki=144/156 nM).

Fluorocitabine HCl, a cytarabine analog, hydrolyzes into ara-FC and ara-FU, showing antitumor effects in leukemia and solid cancers.

5’-O-TBDMS-Bz-dA is a nucleoside with protective and modification effects.

MRK-952 is a NUDIX hydrolase inhibitor. NUDIX enzymes play a role in cellular metabolism, homeostasis, and mRNA processing.

CDK2-IN-43 (Compound 3a) is a CDK2-cyclin E2 inhibitor with an IC50 value of 6.0 nM. It is applicable to cancer research.

DHFR-IN-8 (compound 6r), a dihydrofolate reductase (DHFR) inhibitor, disrupts purine and thymidylate biosynthesis critical for cell proliferation and growth.

MYC-IN-2 is a protein-protein inhibitor targeting the MYC protein, designed for use in cancer research.

CDK5-IN-1: Potent CDK5 inhibitor (<10 nM) used in kidney disease research.

DSPE-PEG5000-cRGD is a PEG compound composed of DSPE and an αvβ3 targeting peptide (cRGD). The cRGD peptide has the ability to specifically bind to the αvβ3 present on the surfaces of numerous cancer cells and new vascular cells. DSPE-PEG5000-cRGD is useful for drug delivery applications.

Anti-EMMPRIN/CD147 Antibody is a human-derived antibody expressed in CHO cells, targeting Basigin. For an isotype control, refer to HumanIgG1kappa, Isotype Control.

5-Caroxy uracil-1-yl acetic acid benzyl ester, a purine analog, inhibits DNA synthesis and induces apoptosis to combat lymphoid cancers.

K34c hydrochloride is an alpha5β1 integrin antagonist for glioblastoma study.

6-Amino-4-hydrozino-2-(β-D-ribofuranosyl)-2H-pyrazolo[3,4-d]pyrimidine is a purine nucleoside analogue with broad antitumor activity, particularly against

Compound PDK0016, with CAS No. 108-53-2, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound PDK0016 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Uridine triphosphate 13C9,15N2 sodium is an isotopically labeled.UTP is a key in RNA synthesis molecule a substrate for RNA polymerase.

ROCK-IN-5 (I-B-37) inhibits kinases like ROCK/ERK/GSK; may aid in cardiac and neuro disease studies.

1-(β-D-Xylofuranosyl)-N6-(m-methoxybenzyl)adenine is an adenosine analog.

HDAC-IN-85 (Compound 1) is an HDAC inhibitor capable of crossing the blood-brain barrier. It exhibits inhibitory effects on brain tumor cell lines and can induce acetylation, resulting in DNA double-strand breaks and promoting RAD51 ubiquitination, which disrupts the DNA repair process. HDAC-IN-85 is applicable in studies of glioblastoma.

N3,5-Dimethyl-2’-O-(2-methoxyethyl) uridine, a purine nucleoside analog, exhibits broad antitumor activity, particularly against indolent lymphoid malignancies.

Stigmatellin is an antibiotic derived from the cell mass of the myxobacterium, effective against yeasts (yeasts), filamentous fungi (filamentous fungi), and several Gram-positive bacteria (Gram-positive bacteria). Additionally, it serves as a potent inhibitor of photosynthetic electron (photosynthetic electron) transfer. Stigmatellin utilizes various sugars, polysaccharides, and acids from the citric acid cycle as substrates, inhibiting RNA and protein synthesis. It has two different inhibitory sites: one located on the reducing side of photosystem II and the other at the cytochrome b6/f complex. Stigmatellin holds potential for use in antimicrobial and photosynthesis research.

IRE1α kinase-IN-6 is a potent IRE1α inhibitor with an IC 50 value of 4.4 nM.

2’-Chloro-N6-(3-trifluoromethyl)benzyl adenosine, a purine nucleoside analog, exhibits broad antitumor activity, particularly against indolent lymphoid

α4β1 integrin (VLA-4) ligand (Kd ~ 12 nM). Non-fluorescent derivative of LDV FITC.

Remdesivir metabolite, antiviral nucleoside analog, effective against SARS-CoV and MERS-CoV.

Esperamicin A1, a powerful antitumor drug, comes from Actinomadura verrucosospora.

Pseudouridimycin: a C-nucleoside antibiotic, inhibits bacterial RNAP, targets Gram-negative and Gram-positive bacteria.

6-Amino-3-(furan-2-yl)-4-methoxy-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine, a purine nucleoside analogue, exhibits broad antitumor activity by

PKMYT1-IN-3 (compound 8ma) is a potent, selective inhibitor of PKMYT1, demonstrating an IC50 of 16.5 nM and exhibiting antitumor activity.

DSPE-PEG2000-iRGD is a PEG compound composed of DSPE and the αv-integrin targeting peptide (iRGD). The iRGD peptide binds to αv-integrins and subsequently undergoes proteolytic cleavage within tumors, producing CRGDK/R, which interacts with neuropilin-1. This compound is characterized by its tumor-targeting and tumor-penetrating properties, making DSPE-PEG2000-iRGD suitable for drug delivery applications.

2'-Deoxy-2'-fluoro-1-uridine: an L-nucleoside, inhibits RNA viruses by blocking viral RNA polymerase.

Phen-DC3 Trifluoromethanesulfonate targets G-quadruplexes and inhibits FANCJ/DinG helicases; IC50s: 65±6/50±10 nM.

SP27, a selective PROTAC, degrades PLK4 with a DC50 of 19.5 nM and may be utilized in breast cancer research [1].

5'-O-DMT-2'-O-TBDMS-rI, a modified nucleoside, finds application in deoxyribonucleic acid (DNA) or nucleic acid synthesis.